Lupin acquires diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim

In a strategic move to fortify its position in the pharmaceutical domain, global major Lupin Limited proclaimed its acquisition of coveted diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim International GmbH. These brands, which Lupin has been marketing since 2015 under a co-marketing arrangement, come with the added bonus of trademark rights.

India grapples with a staggering number of Type-2 Diabetes patients, with approximately 77 million individuals over the age of 18 affected by the ailment and another 25 million pre-diabetic citizens, teetering on the brink of full-blown diabetes. ONDERO (Linagliptin) and ONDERO MET (Linagliptin + Metformin) stand as paramount treatments in diabetes care, and this acquisition further showcases Lupin’s unwavering commitment to the diabetic community.

Nilesh Gupta, Managing Director at Lupin, shared his views on the acquisition, emphasizing Lupin’s ongoing dedication to quality pharmaceutical offerings. “By integrating ONDERO and ONDERO MET into our repertoire,” he said, “we’re not only diversifying our product portfolio but cementing our place as a formidable force in the anti-diabetes sector.”

Rajeev Sibal, President – India Region Formulations at Lupin, highlighted the increasing burden of diabetes, driven by rising obesity rates and detrimental lifestyle choices. He stated, “This acquisition is a testament to our relentless commitment to enabling healthcare professionals in their battle against the escalating threat of diabetes in India, ultimately bettering the lives of countless patients.”